DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Fluocinolone (Fluocinolone Acetonide Topical) - Published Studies

 
 



Fluocinolone Related Published Studies

Well-designed clinical trials related to Fluocinolone (Fluocinolone Acetonide Topical)

Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial. [2011.10]

Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial. [2011.08]

Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. [2011.04]

Fluocinolone acetonide implantable device for diabetic retinopathy. [2011.03.01]

Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert. [2010.07]

Evaluation of an intravitreal fluocinolone acetonide implant versus standard systemic therapy in noninfectious posterior uveitis. [2010.03]

Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results. [2008.09]

A randomized controlled trial of the efficacy and safety of a fixed triple combination (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) compared with hydroquinone 4% cream in Asian patients with moderate to severe melasma. [2008.09]

A randomized controlled trial of the efficacy and safety of a fixed triple combination (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) compared with hydroquinone 4% cream in Asian patients with moderate to severe melasma. [2008.06.28]

Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. [2006.06]

Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis. [2005.07]

Well-designed clinical trials possibly related to Fluocinolone (Fluocinolone Acetonide Topical)

Challenges in the design and implementation of the Multicenter Uveitis Steroid Treatment (MUST) Trial - lessons for comparative effectiveness trials. [2011.10.12]

Morphologic assessment for glaucoma in the Multicenter Uveitis Steroid Treatment (MUST) trial. [2011.08]

Validation of a photographic vitreous haze grading technique for clinical trials in uveitis. [2011.08]

Intranasal flunisolide treatment in patients with non-allergic rhinitis. [2011.04]

Sequential treatment with triple combination cream and intense pulsed light is more efficacious than sequential treatment with an inactive (control) cream and intense pulsed light in patients with moderate to severe melasma. [2011.02]

Effects of a novel formulation of fluocinonide 0.1% cream on skin barrier function in atopic dermatitis. [2011.02]

Low-fluence Q-switched neodymium-doped yttrium aluminum garnet laser for melasma with pre- or post-treatment triple combination cream. [2010.06]

The multicenter uveitis steroid treatment trial: rationale, design, and baseline characteristics. [2010.04]

The multicenter uveitis steroid treatment trial: rationale, design, and baseline characteristics. [2010.04]

High-dose inhaled flunisolide versus budesonide in the treatment of acute asthma exacerbations in preschool-age children. [2009.04]

Prevention of surgery in children with adenoidal hypertrophy treated with intranasal flunisolide: a 12-month follow-up. [2009.04]

Vitamin D3 is not effective in the treatment of chronic chilblains. [2009.02]

A single-center, double-blind, randomized trial of the atrophogenic effects of fluocinonide cream 0.1% versus clobetasol propionate cream 0.05% in participants with corticosteroid-responsive dermatoses. [2008.06]

Intranasal flunisolide treatment in children with adenoidal hypertrophy. [2007.10]

Strength and endurance of the respiratory and handgrip muscles after the use of flunisolide in normal subjects. [2007.07]

A hydroquinone formulation with increased stability and decreased potential for irritation. [2007.06]

A comparison of triple combination cream and hydroquinone 4% cream for the treatment of moderate to severe facial melasma. [2007.03]

Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: updated results from an ongoing trial. [2006.04]

Inhaled flunisolide suppresses the hypothalamic-pituitary-adrenocortical axis, but has minimal systemic immune effects in healthy cats. [2006.01]

Efficacy of nebulized flunisolide combined with salbutamol and ipratropium bromide in stable patients with moderate-to-severe chronic obstructive pulmonary disease. [2006]

A large 12-month extension study of an 8-week trial to evaluate the safety and efficacy of triple combination (TC) cream in melasma patients previously treated with TC cream or one of its dyads. [2005.09]

Effects of drug treatment on inflammation and hyperreactivity of airways and on immune variables in cats with experimentally induced asthma. [2005.07]

Other research related to Fluocinolone (Fluocinolone Acetonide Topical)

Cytomegalovirus endotheliitis after fluocinolone acetonide (Retisert) implant in a patient with Behcet uveitis. [2011.08]

Use of a high infusion rate to prevent posterior dislocation of fluocinolone acetonide implant during surgical removal. [2011.06]

Fluocinolone acetonide implant (Retisert) for chronic cystoid macular edema in two patients with AIDS and a history of cytomegalovirus retinitis. [2011.06]

Outcomes of birdshot chorioretinopathy treated with an intravitreal sustained-release fluocinolone acetonide-containing device. [2011.04]

Effect of fluocinolone acetonide on human dental pulp cells: cytotoxicity, proliferation, and extracellular matrix formation. [2011.02]

Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial. [2011]

Fluocinolone acetonide implantable device for diabetic retinopathy. [2011]

Cost-effectiveness of a hydroquinone/tretinoin/fluocinolone acetonide cream combination in treating melasma in the United States. [2010.09]

Intravitreous delivery of the corticosteroid fluocinolone acetonide attenuates retinal degeneration in S334ter-4 rats. [2010.08]

Scleral thickness following fluocinolone acetonide implant (Retisert). [2010.08]

Combined fluocinolone acetonide intravitreal insertion and glaucoma drainage device placement for chronic uveitis and glaucoma. [2010.05]

Evaluation of an intravitreal fluocinolone acetonide implant versus standard systemic therapy in noninfectious posterior uveitis. [2010]

A histological examination for skin atrophy after 6 months of treatment with fluocinolone acetonide 0.01%, hydroquinone 4%, and tretinoin 0.05% cream. [2009.12]

Fluocinolone acetonide intravitreal implants in Vogt-Koyanagi-Harada disease. [2009.11]

Photoreceptor neuroprotection in RCS rats via low-dose intravitreal sustained-delivery of fluocinolone acetonide. [2009.10]

Expression of IFN-gamma before and after treatment of oral lichen planus with 0.1% fluocinolone acetonide in orabase. [2009.10]

Management of fluocinolone implant dissociation during implant exchange. [2009.09]

Fluocinolone acetonide 0.01% in peanut oil: safety and efficacy data in the treatment of childhood atopic dermatitis in infants as young as 3 months of age. [2009.05]

Management of sympathetic ophthalmia with the fluocinolone acetonide implant. [2009.03]

Combined fluocinolone acetonide intraocular delivery system insertion, phacoemulsification, and intraocular lens implantation for severe uveitis. [2008.10]

Fluocinolone acetonide sustained drug delivery device for chronic central retinal vein occlusion: 12-month results. [2008.08]

Treatment of serpiginous choroiditis with intravitreous fluocinolone acetonide implant. [2008.05]

Reimplantation of a fluocinolone acetonide sustained drug delivery implant for chronic uveitis. [2008.04]

Stem cells in the hair follicle and interfollicular epidermis of mice following topical application of fluocinolone acetonide. [2007.12]

Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants. [2007.11]

Intraocular Pressure in Patients With Uveitis Treated With Fluocinolone Acetonide Implants. [2007.10.08]

Cost-effectiveness of a fixed combination of hydroquinone/tretinoin/fluocinolone cream compared with hydroquinone alone in the treatment of melasma. [2007.02]

Cytomegalovirus retinitis after fluocinolone acetonide (Retisert) implant. [2007.02]

Fluocinolone acetonide intravitreal sustained release device--a new addition to the armamentarium of uveitic management. [2007]

Long-term release of fluocinolone acetonide using biodegradable fumarate-based polymers. [2006.08.28]

Efficacy of low-release-rate fluocinolone acetonide intravitreal implants to treat experimental uveitis. [2006.07]

Expression of TNF-alpha in oral lichen planus treated with fluocinolone acetonide 0.1%. [2006.03]

Hydroquinone 4%, tretinoin 0.05%, fluocinolone acetonide 0.01%: a safe and efficacious 12-month treatment for melasma. [2005.01]

Other possibly related research studies

Nebulized drug admixtures: effect on aerosol characteristics and albuterol output. [2006.01]

Validation of a melasma quality of life questionnaire for Brazilian Portuguese language: the MelasQoL-BP study and improvement of QoL of melasma patients after triple combination therapy. [2006.12]

Intravitreal steroids in the management of macular oedema. [2006.12]

Postinflammatory hyperpigmentation: evolving combination treatment strategies. [2006.08]

Community-based trial of a triple-combination agent for the treatment of facial melasma. [2006.03]

Retisert (Bausch & Lomb/Control Delivery Systems). [2005.11]

Evidence of remodeling in peripheral airways of patients with mild to moderate asthma: effect of hydrofluoroalkane-flunisolide. [2005.11]

Gateways to clinical trials. [2005.06]

The nitrosterols--a step forward from the steroid anti-inflammatory drugs? [2005.07]

The safety profile of long-term, high-dose intraocular corticosteroid delivery. [2005.03]

Transient band-like keratopathy after treatment for seborrheic dermatitis. [2005.04]

Flunisolide decreases exhaled nitric oxide and nitrotyrosine levels in asthmatic children. [2006]

Topical glucocorticosteroids in rhinitis: clinical aspects. [2006.10]

Retisert: is the new advance in treatment of uveitis a good one? [2007.03]

Drug delivery methods for posterior segment disease. [2007.05]

Hypertrichosis as a side effect of inhaled steroids in children. [2007.04]

Treating chronic noninfectious posterior segment uveitis: the impact of cumulative damage. Proceedings of an expert panel roundtable discussion. [2006.10]

Compressor/nebulizers differences in the nebulization of corticosteroids. The CODE study (Corticosteroids and Devices Efficiency). [2007.07]

Emerging therapies for the treatment of neovascular age-related macular degeneration and diabetic macular edema. [2007]

Ethnic considerations in the treatment of Hispanic and Latin-American patients with hyperpigmentation. [2006.12]

Lichenoid and other clinical presentations of atopic dermatitis in an inner city practice. [2008.03]

Intravitreal steroids for macular edema in diabetes. [2008.01.23]

A reappraisal of the clinical efficacy of nebulized flunisolide in pediatric asthma: the Italian experience. [2007.11]

Pharmacotherapies for diabetic retinopathy: present and future. [2007]

Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasis. [2008.05]

An efficacy study of 3 commercially available hydroquinone 4% treatments for melasma. [2007.12]

In vivo determination of the skin atrophy potential of the super-high-potency topical corticosteroid fluocinonide 0.1% cream compared with clobetasol propionate 0.05% cream and foam, and a vehicle. [2008.01]

Intravitreal steroid slow-release device replacing repeated intravitreal triamcinolone injections for sympathetic ophthalmia. [2008.09]

Iluvien: a new sustained delivery technology for posterior eye disease. [2008.09]

Nebulisation of corticosteroid suspensions and solutions with a beta(2) agonist. [2008.05]

Update on treatments for diabetic macular edema. [2008.05]

CO2 laser evaporation of oral lichen planus. [2008.07]

Successful treatment of moderate to severe melasma with triple-combination cream and glycolic acid peels: a pilot study. [2008.11]

Reticulated phototoxic eruption in a patient on long-term diltiazem therapy. [2008.08]

Hyperpigmentation: old problem, new therapies. [2009.09]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017